JP7213186B2 - 抗ｔｇｆベータ抗体およびそれらの使用 - Google Patents

抗ｔｇｆベータ抗体およびそれらの使用 Download PDF

Info

Publication number
JP7213186B2
JP7213186B2 JP2019539214A JP2019539214A JP7213186B2 JP 7213186 B2 JP7213186 B2 JP 7213186B2 JP 2019539214 A JP2019539214 A JP 2019539214A JP 2019539214 A JP2019539214 A JP 2019539214A JP 7213186 B2 JP7213186 B2 JP 7213186B2
Authority
JP
Japan
Prior art keywords
antibody
tgf
cancer
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019539214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514310A5 (https=
JP2020514310A (ja
Inventor
ゲイリー・シャピロ
ケビン・ブローワー
パトリック・フィン
リチャード・シー・グレゴリー
ラオ・コドゥリ
フェン・リウ
ナタリア・マリコフ
パーミンンダー・マンクゥ
ジャック・アール・ポラード
ファーウェイ・チウ
ヨアヒム・タイルハーバー
クリストファー・ウィンター
マルセラ・ユー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/IB2018/000088 external-priority patent/WO2018134681A1/en
Publication of JP2020514310A publication Critical patent/JP2020514310A/ja
Publication of JP2020514310A5 publication Critical patent/JP2020514310A5/ja
Priority to JP2023003484A priority Critical patent/JP7411832B2/ja
Application granted granted Critical
Publication of JP7213186B2 publication Critical patent/JP7213186B2/ja
Priority to JP2023216508A priority patent/JP7844425B2/ja
Priority to JP2025202422A priority patent/JP2026036696A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019539214A 2017-01-20 2018-01-19 抗ｔｇｆベータ抗体およびそれらの使用 Active JP7213186B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023003484A JP7411832B2 (ja) 2017-01-20 2023-01-13 抗ｔｇｆベータ抗体およびそれらの使用
JP2023216508A JP7844425B2 (ja) 2017-01-20 2023-12-22 抗ｔｇｆベータ抗体およびそれらの使用
JP2025202422A JP2026036696A (ja) 2017-01-20 2025-11-25 抗ｔｇｆベータ抗体およびそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
US62/448,800 2017-01-20
EP17305061.8 2017-01-20
EP17305061 2017-01-20
PCT/IB2018/000088 WO2018134681A1 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023003484A Division JP7411832B2 (ja) 2017-01-20 2023-01-13 抗ｔｇｆベータ抗体およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2020514310A JP2020514310A (ja) 2020-05-21
JP2020514310A5 JP2020514310A5 (https=) 2021-02-18
JP7213186B2 true JP7213186B2 (ja) 2023-01-26

Family

ID=61656071

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019539214A Active JP7213186B2 (ja) 2017-01-20 2018-01-19 抗ｔｇｆベータ抗体およびそれらの使用
JP2023003484A Active JP7411832B2 (ja) 2017-01-20 2023-01-13 抗ｔｇｆベータ抗体およびそれらの使用
JP2023216508A Active JP7844425B2 (ja) 2017-01-20 2023-12-22 抗ｔｇｆベータ抗体およびそれらの使用
JP2025202422A Pending JP2026036696A (ja) 2017-01-20 2025-11-25 抗ｔｇｆベータ抗体およびそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023003484A Active JP7411832B2 (ja) 2017-01-20 2023-01-13 抗ｔｇｆベータ抗体およびそれらの使用
JP2023216508A Active JP7844425B2 (ja) 2017-01-20 2023-12-22 抗ｔｇｆベータ抗体およびそれらの使用
JP2025202422A Pending JP2026036696A (ja) 2017-01-20 2025-11-25 抗ｔｇｆベータ抗体およびそれらの使用

Country Status (22)

Country Link
US (4) US10766955B2 (https=)
JP (4) JP7213186B2 (https=)
CN (2) CN117417939A (https=)
AU (2) AU2018209391B2 (https=)
BR (1) BR112019014787A2 (https=)
CA (1) CA3050845A1 (https=)
CL (1) CL2019002011A1 (https=)
CO (1) CO2019008946A2 (https=)
CR (1) CR20190375A (https=)
DO (1) DOP2019000191A (https=)
EC (1) ECSP19059553A (https=)
IL (3) IL268112B2 (https=)
MA (1) MA47311A (https=)
MX (2) MX2019008551A (https=)
MY (1) MY200751A (https=)
NZ (1) NZ796440A (https=)
PE (1) PE20200734A1 (https=)
PH (1) PH12019501635A1 (https=)
SG (1) SG11201906660TA (https=)
TW (3) TW202506185A (https=)
UY (1) UY37575A (https=)
ZA (1) ZA201904494B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
TW202019962A (zh) * 2018-07-10 2020-06-01 法商賽諾菲公司 標靶CD38及TGF-β的組合療法
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3124415A1 (en) * 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
AU2022294100A1 (en) 2021-06-18 2024-02-01 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
WO2023019215A1 (en) 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
US20230144192A1 (en) * 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
KR20250004747A (ko) 2022-04-13 2025-01-08 이뮤니티바이오, 인크. 생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528993A (ja) 2007-05-31 2010-08-26 ゲンマブ エー／エス 安定なＩｇＧ４抗体
JP2014514287A (ja) 2011-03-29 2014-06-19 ロシュ グリクアート アーゲー 抗体Ｆｃ変種
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
JP2016519093A (ja) 2013-03-20 2016-06-30 ジェンザイム・コーポレーション 骨形成不全症の処置方法
WO2016141245A1 (en) 2015-03-04 2016-09-09 Genzyme Corporation Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
US20160289315A1 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of Cancer Using Inhibitors of TGF-BETA and PD-1

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
NZ554885A (en) 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2855527B1 (en) 2012-05-31 2018-08-01 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2908913B1 (en) * 2012-10-17 2018-10-03 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
WO2016057933A1 (en) 2014-10-10 2016-04-14 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
JP2019533003A (ja) 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528993A (ja) 2007-05-31 2010-08-26 ゲンマブ エー／エス 安定なＩｇＧ４抗体
JP2014514287A (ja) 2011-03-29 2014-06-19 ロシュ グリクアート アーゲー 抗体Ｆｃ変種
JP2016519093A (ja) 2013-03-20 2016-06-30 ジェンザイム・コーポレーション 骨形成不全症の処置方法
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2016141245A1 (en) 2015-03-04 2016-09-09 Genzyme Corporation Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
US20160289315A1 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of Cancer Using Inhibitors of TGF-BETA and PD-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL IMMUNOLOGY，2001年02月，VOL:98, NR:2，PAGE(S):164 - 174
Molecular Immunology，1993年，Vol.30, No.1，pp.105-108

Also Published As

Publication number Publication date
AU2018209391B2 (en) 2024-08-15
SG11201906660TA (en) 2019-08-27
MX2019008551A (es) 2020-01-27
US20220195026A1 (en) 2022-06-23
US10766955B2 (en) 2020-09-08
TWI856437B (zh) 2024-09-21
IL323799A (en) 2025-12-01
CN110520441B8 (zh) 2024-07-09
TW201833135A (zh) 2018-09-16
JP7411832B2 (ja) 2024-01-11
CN117417939A8 (zh) 2024-07-12
DOP2019000191A (es) 2019-10-15
MA47311A (fr) 2019-11-27
NZ796440A (en) 2025-12-19
UY37575A (es) 2018-10-31
TW202506185A (zh) 2025-02-16
IL311866A (en) 2024-06-01
JP7844425B2 (ja) 2026-04-13
TW202313678A (zh) 2023-04-01
AU2018209391A1 (en) 2019-09-05
NZ756431A (en) 2025-03-28
US11242384B2 (en) 2022-02-08
IL268112B1 (en) 2025-05-01
ZA201904494B (en) 2020-12-23
CR20190375A (es) 2019-12-17
CA3050845A1 (en) 2018-07-26
IL311866B2 (en) 2026-03-01
US20200399358A1 (en) 2020-12-24
JP2020514310A (ja) 2020-05-21
CO2019008946A2 (es) 2019-09-30
IL268112A (en) 2019-09-26
JP2026036696A (ja) 2026-03-05
US20180244763A1 (en) 2018-08-30
US12049496B2 (en) 2024-07-30
IL268112B2 (en) 2025-09-01
ECSP19059553A (es) 2019-08-30
TWI787230B (zh) 2022-12-21
JP2024038040A (ja) 2024-03-19
CL2019002011A1 (es) 2019-11-22
US20250026821A1 (en) 2025-01-23
PH12019501635A1 (en) 2019-11-04
BR112019014787A2 (pt) 2020-02-27
CN117417939A (zh) 2024-01-19
CN110520441A (zh) 2019-11-29
PE20200734A1 (es) 2020-07-23
CN110520441B (zh) 2023-11-14
MY200751A (en) 2024-01-13
JP2023052376A (ja) 2023-04-11
AU2024264593A1 (en) 2024-12-05
IL311866B1 (en) 2025-11-01
MX2023002588A (es) 2023-03-22

Similar Documents

Publication Publication Date Title
JP7411832B2 (ja) 抗ｔｇｆベータ抗体およびそれらの使用
WO2018134681A1 (en) Anti-tgf-beta antibodies and their use
CA3019921A1 (en) Methods for monitoring and treating cancer
KR20210096598A (ko) Ilt2에 대한 항체 및 이의 용도
JP2019515670A (ja) がんをモニタリングし治療するための方法
US20220378909A1 (en) Methods of Treating Cancer with Anti-PD-1 Antibodies
HK40106689A (zh) 抗TGF-β抗体及其用途
KR102699080B1 (ko) 항-tgf-베타 항체 및 이의 용도
EA049204B1 (ru) Антитела к tgf-бета и их применение
EA041300B1 (ru) Антитела к tgf-бета и их применение
HK40002465A (en) Methods for monitoring and treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230116

R150 Certificate of patent or registration of utility model

Ref document number: 7213186

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250